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INTRODUCTION
Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2), has created an unprecedented global health crisis. Because of
its recent emergence, there is paucity of knowledge on viral pathogenesis and host immune
responses to SARS-CoV-2. Most of the currently published research has explored either
the host immune response (i.e., host immunopathology) or SARS-CoV-2 lung epithelium
tropism (i.e., viral pathogenesis) (1–3). Acute respiratory distress syndrome (ARDS), cytokine
storm, lymphopenia and exhausted lymphocytes (in particular T cells) are the most proposed
immunopathological phenotypes, while cellular injury due to virus-host interactions and interferon
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(IFN) dysregulation are well-described for viral pathogenesis
(1, 3). Despite these insights, COVID-19 remains a “moving
immunological concept” due to frequent disagreements in
literature over some major immunological characteristics. In this
opinion, we organize the current knowledge and integrate some
hypotheses and anticipated challenges into a broad COVID-19
“immunome” paradigm, i.e., the entirety of processes defining
the overall immunological phenotypes or inclusive phenome
(see legend of Figure 1), that is exploitable for guiding future
mechanistic biomarker-mining in longitudinal clinical samples
collected from COVID-19 patients.
COVID-19 IMMUNOPATHOLOGY: “A
MOVING CONCEPT”
The upper respiratory system is the main port-of-entry for
SARS-CoV-2. The infection can eventually progress into
FIGURE 1 | A unified COVID-19 “immunome” model integrating lung-associated pathophysiology with systemic immunopathology, together accounting for the
SARS-CoV-2/COVID19 immunological paradigm. SARS-CoV-2 exhibits increased (direct) tropism toward ACE2+ epithelial cells within the lungs and upper-airways
that, due to viral replication, ultimately results in epithelial cell death and epithelium disruption. This is paralleled by disruption of type I interferon (IFN) responses within
infected cells, possibly due to direct interference by SARS-CoV-2 derived anti-IFN modules. This is accompanied by release of damage-associated molecular patterns
(DAMPs; coming from dying/dead epithelial cells) as well as pathogen-associated molecular patterns (PAMPs; coming from viral genetic material and immunogenic
proteins). These events, together with the above viral pathogenic events, fuel dysregulated myeloid hyperinflammation. In addition, through as-yet-unclear
mechanisms, SARS-CoV-2 may also exert direct or indirect cytopathic effects on myeloid immune cells, thereby further facilitating immune dysregulation. These
events together characterize the COVID-19-associated ARDS phenotype. This ARDS can: (I) on one hand, facilitate systemic cytokine-driven hyperinflammation; yet
(II) on the other hand, stress the lymphoid organs by demanding increased recruitment of immune cells for resolution of inflammation. Such prolonged immunological
stress accompanied by cytokine-based inflammation facilitates lymphopenia, typically observed in COVID-19 patients (and may also cause lymphoid organ failure if
this stressful situation prolongs, as seen in some critically ill patients). Herein, there is some evidence that SARS-CoV-2 may exert (in)direct cytopathic effects against
lymphocytes thereby further fuelling lymphopenia. Together these processes define the overall immunological phenotypes or inclusive phenome (i.e., “immunome”) of
COVID-19.
hyperinflammation in the lungs, and in severe cases into
respiratory insufficiency and ARDS (2) - see overview in
Figure 1. This negative clinical evolution is almost always
accompanied by a dysregulated local and systemic immune
response, comprising hyperactive circulating as well as lung-
infiltrating myeloid immune cells (especially monocytes,
macrophages and neutrophils). Their activation is triggered by
virus-associated or induced pathogen- and damage-associated
molecular patterns (i.e., PAMPs and DAMPs) and results in an
excessive release of chemokines and inflammatory cytokines
(1, 2, 4, 5). It has been proposed that this excessive production
of cytokines is reminiscent of a typical cytokine-release
syndrome (CRS), which in COVID-19 is coupled to reduced
IFN production and a defective antiviral defense (3, 6, 7).
However, in-depth insights into the innate immune hyperactivity
in COVID-19 are still lacking. Moreover, in most COVID-
19 patients that require hospitalization, there is a striking
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lymphopenia that correlates with clinical severity and involves all
lymphocyte subpopulations (1–3). In addition lymphocyte subset
alterations have been observed and indeed, CD8 T- and B-cell
quantities as well as CD4/CD8 ratio seem to act as independent
predictors of COVID-19 survival (8). A major question, however,
remains how myeloid hyperactivation and T-/B-cell dysfunction
contribute to SARS-CoV-2 immunopathology. Also, can SARS-
CoV-2 exert direct and indirect cytopathic effects on immune
cells? For this to happen, an alternative SARS-CoV-2 “entry
mechanism,” other than the one for respiratory epithelial cells
involving viral spike-glycoproteins and angiotensin-converting
enzyme 2 (ACE2) receptor interaction, must exist for immune
cells that do not strongly express ACE2 receptors (2, 3, 9). In this
regard, on the one hand SARS-CoV-2 may gain cellular entry
via the CD147 receptor that is widely expressed on immune
cells, accounting for direct immunocytopathic effects (10, 11).
On the other hand, in analogy with e.g., dengue and influenza
viruses (12), an indirect immunocytopathy may exist through
antibody-dependent enhancement (ADE) mechanisms, in which
non-neutralizing virus-specific antibodies may facilitate viral
entry into myeloid cells via Fc receptors-mediated phagocytosis
or efferocytosis (13). However, the uptake of viral particles via
such mechanisms will be suboptimal, leading to inflammatory
activation of infected cells but not orderly viral degradation (12).
This hypothesis is intriguing because it has been observed that a
small fraction of COVID-19 patients that mount early (possibly
low-quality) antibody responses against SARS-CoV-2, tend to
suffer from more severe symptoms (12). Moreover, COVID-
19 patients with agammaglobulinemia and negligible B-cells
presence may have a milder clinical course of COVID-19 (14).
Unfortunately, little is known on the exact interactions between
SARS-CoV-2 on immune cells, thereby presenting an additional
important knowledge gap that needs to be addressed urgently.
SARS-CoV-2: FROM CELLULAR
PATHOGENESIS TO IMMUNOLOGICAL
CONSEQUENCES
Another level of immune-dysregulation during COVID-19
is positioned at the antiviral immunity induced by SARS-
CoV-2-infected cells. A normal antiviral response involves a
sustained type I/III interferon (IFN) cytokine-response that
activates IFN-stimulated-genes (ISGs), which then orchestrate a
multi-parametric program of antiviral defenses (2, 15). SARS-
CoV-2 can disrupt these protective inflammatory reactions
by blunting type I/III IFN-cytokines, while increasing other
pro-inflammatory cytokines (6, 7). This imbalanced cytokine
response can impede efficient inhibition of viral replication and
viral clearance (7). Whole blood RNA-profiling indeed showed
that critically-ill COVID-19 patients initiate inefficient type I
IFNs-responses, have reduced ISGs and persistent (blood-borne)
viral load, and show an exacerbated inflammatory response
driven by IL6, TNF, and IL1β/IL1RA (6). Importantly, these
dysregulations are capable of driving immunocytopathic or
immune cell death phenomena e.g., apoptosis/necroptosis
in lymphocytes or pyroptosis and NETosis in neutrophils,
thereby further worsening inflammation (4, 16). Moreover,
human population-related genetic variation studies have
shown that evolution-driven natural selection has targeted
the human IFNs pathway with variable (purifying) selection
or (geographically-restricted) positive selection (17). Thus,
various human populations may differ widely in terms of
their anti-viral IFNs pathway mechanics. And this may further
account for heterogeneity in COVID-19 symptoms and
progression. Together this again illustrates the importance of
connecting characteristics of SARS-CoV-2 viral pathogenesis
with host immunopathological characteristics to fully unravel
COVID-19 pathophysiology.
COVID-19 “IMMUNOME”: HOW TO
CONCEPTUALIZE AND STUDY A UNIFIED
PARADIGM?
Successful COVID-19 patient management and therapeutic
intervention will likely relies on comprehensively integrating
all knowledge on SARS-CoV2-tropism and COVID-19-
immunopathology into a single unified “immunome”-paradigm.
The integration of currently published evidence (1–3) and
preliminary working-hypotheses (6, 7, 10, 12, 14) indicates
a spatio-temporal immune-dysregulation during COVID-
19. In particular, we present a model of two cross-talking
immunopathologies (Figure 1), which may both culminate
into indirect and/or direct immune-cytopathic effects:
(i) a viral tropism-based lung infection (VLI) leading to
cytokine-driven hyperinflammation coupled with dysfunctional
IFN-responses that impede viral clearance at the entry site
(upper respiratory airways/lungs); and (ii) collateral systemic
immune-dysregulation (CSID) resulting from an excessive
and ineffective triggering of myeloid immune cells (3, 18–
21). The latter may further drive an uncoordinated cytokine
response compromising proficient lymphocytic and NK cell
functioning (22). Moreover, we propose that when VLI is
excessive and progressing in a very short time frame, this
may rapidly “titrate” several important immune cells away
from systemic presence for resolution of the lung-associated
inflammation, thereby stressing the lymphoid organs (3). If
this extreme immunological imbalance continues without
resolution of the lung inflammation, it may pave the way
for a depletion-like phenotype for certain immune cells and
facilitate CSID (23). We hypothesize that these combined
immunopathologies may further hamper a correct antiviral
(protective) T-/B-cell response through mechanisms that have
not been comprehensively elucidated. The inter-individual
determinants and risk factors for various inflammatory
pathways are currently unknown, and more knowledge is
necessary to refine our model. Clearly, it is important to rapidly
understand the cause-effect components of the COVID-19-
associated inflammatory cycle: i.e., it is essential to differentiate
whether genotype-specific differences in the (innate) immune
response are causing COVID-19 pathology or whether the
immunological phenotype is a consequence of its rapidly
mounting pressure on the host immune-inflammatory system.
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In the end, a combination of both intrinsic host-related
immune features and an excessive persistent viral attack on the
immune system can be mediating the pathological features of
COVID-19.
Confirming this model on a mechanistic level would require
a high degree of harmony between methodological initiatives
and clinical study-design, starting with the collection of
dedicated and hard-to-get (invasive) patient samples. These
should include samples of different tissues (lung, heart, spleen,
liver, bone marrow and lymph nodes upon autopsy, and
bronchoalveolar lavage), and longitudinal blood samples.
For instance, there is a huge scarcity of high quality autopsy
analyses in COVID-19 deceased patients, thereby severely
compromising our understanding of this complex disease in the
terminal time-frame (24). In addition to basic immunoprofiling
technologies (flow cytometry/cytokine profiling), single
cell-transcriptomics should be included in the workflow. This
will allow in-depth dissection of the fundamental immune
cell-states: i.e., immune cell differentiation and functional
trajectories as well as discrimination of virus infected or
uninfected immune cells. Such integrated knowledge will play
a major role in understanding COVID-19 pathophysiology
and will serve as input for dedicated drug discovery pipelines.
For instance, a recent clinical trial that accounts for both
viral pathogenesis and immunopathology, by administrating
triple-therapy consisting of IFN-1β, lopinavir-ritonavir and
ribavirin, alleviated symptoms, suppressed IL-6 levels and
shortened duration of viral-shedding and hospital stay in
mild-to-moderate COVID-19 patients (9). Similar multi-level
therapeutic solutions are required for severely ill patients and
need to consider the multi-parametric nature of COVID-19.
Thus, a COVID-19 “immunome” driven approach can lead to
better patient management and therapeutic decisions.
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